1. Home
  2. SCM vs ANL Comparison

SCM vs ANL Comparison

Compare SCM & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$10.11

Market Cap

397.8M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

SELL

Current Price

$8.28

Market Cap

350.9M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
SCM
ANL
Founded
2012
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
397.8M
350.9M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
SCM
ANL
Price
$10.11
$8.28
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$13.00
$16.00
AVG Volume (30 Days)
293.5K
459.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
13.57%
N/A
EPS Growth
123.75
N/A
EPS
0.78
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.01
$0.88
52 Week High
$15.48
$12.09

Technical Indicators

Market Signals
Indicator
SCM
ANL
Relative Strength Index (RSI) 23.88 52.82
Support Level N/A $1.36
Resistance Level $12.40 $12.09
Average True Range (ATR) 0.36 0.82
MACD -0.09 -0.47
Stochastic Oscillator 31.42 36.73

Price Performance

Historical Comparison
SCM
ANL

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: